Fidaxomicin approved for C. difficile infections

Traynor, Kate
July 2011
American Journal of Health-System Pharmacy;7/15/2011, Vol. 68 Issue 14, p1276
Academic Journal
The article reports that the FDA has approved fidaxomicin, a macrolide, for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults and that it will be marketed by Optimer Pharmaceuticals of San Diego, California, and Cubist Pharmaceuticals of Lexington, Massachusetts, as Dificid. Details related to its causes as stated by Centers for Disease Control and Prevention (CDC), its directions for use, its adverse effects and its recommended dosage are provided.


Related Articles

  • Fecal Transplants Promising for Clostridium difficile. Baron, Ellen Jo // Internal Medicine Alert;5/15/2013, Vol. 35 Issue 9, p68 

    The article focuses on the study which assessed the fecal microbiota transplantation (FMT).

  • FDA Clears Test for Bacteria That Can Cause Serious Intestinal Disease.  // Biomedical Market Newsletter;5/5/2011, p787 

    The article reports that the U.S Food and Drug Administration (FDA) has cleared the Cepheid Xpert C. difficile/Epi assay test to rapidly detect the toxin B gene associated with Clostridium difficile infection (CDI) in serious intestinal diseases. It notes that the test determines if the bacteria...

  • Fidaxomicin approved for Clostridium difficile infection.  // WHO Drug Information;2011, Vol. 25 Issue 4, p370 

    No abstract available.

  • After Positive Data, Optimer Rolls with its Fidaxomicin NDA. Young, Donna // BioWorld Today;9/22/2010, Vol. 21 Issue 183, p1 

    The article reports that Optimer Pharmaceuticals Inc. has submitted its rolling new drug application (NDA) for its oral antibiotic fidaxomicin to the U.S. Food and Drug Administration in September 2010. It is stated that the company is seeking to be the first in the U.S. market with an oral...

  • The DIY gut-bug swap. Hamzelou, Jessica // New Scientist;3/1/2014, Vol. 221 Issue 2958, p10 

    The article discusses faecal microbiota transplantation (FMT), focusing on the home application of the treatment by people in the U.S. and Canada where regulations restrict official administration of the procedure. Topics include the technique's reported effectiveness in treating Clostridium...

  • Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. CRAWFORD, TONYA; HUESGEN, EMILY; DANZIGER, LARRY // American Journal of Health-System Pharmacy;6/1/2012, Vol. 69 Issue 11, p933 

    Purpose. The pharmacology, clinical efficacy, safety, dosage and administration, and place in therapy of fidaxomicin for the treatment of Clostridium difficile infection (CDI) are reviewed. Summary. Fidaxomicin, a macrocyclic antibiotic, has a narrow spectrum of activity against gram-positive...

  • Fidaxomicin: Balancing evidence and economics. Stevens, Vanessa; Onufrak, Nikolas; Brown, Jack // American Journal of Health-System Pharmacy;6/1/2012, Vol. 69 Issue 11, p931 

    The authors discuss a study from the issue, by T Crawford and colleagues, which reviews fidaxomicin, first drug approved by FDA, for the treatment of Clostridium difficile infection (CDI). They highlight that although fidaxomicin has a safety profile similar to that of oral vancomycin and has a...

  • Treatment of Clostridium difficile Infection. Gerding, Dale N.; Muto, Carlene A.; Owens Jr., Robert C. // Clinical Infectious Diseases;1/15/2008 Supplement 1, Vol. 46 Issue 1, pS32 

    Recent outbreaks of Clostridium difficile infection (CDI) in North America have been due to a more virulent, possibly more resistant strain that causes more-severe disease, making prompt recognition of cases and optimal management of infection essential for a successful therapeutic outcome....

  • Fecal Microbiota Transplantation: Where Is It Leading.  // Gastroenterology & Hepatology;May2014, Vol. 10 Issue 5, p307 

    Fecal microbiota transplantation (FMT) has gained a great deal of interest in the past year, and controversy briefly hit the news when the US Food and Drug Administration stated, in May of 2013, that an investigational new drug application would be required to perform FMTs and then softened its...

  • Optimer Pharmaceuticals Buoyed by Unanimous Vote. Serebrov, Mari // BioWorld Today;4/6/2011, Vol. 22 Issue 66, p1 

    This article reports that an advisory committee of the U.S. Food and Drug Administration (FDA) has unanimously recommended the approval of Optimer Pharmaceutical Incorporated's Dificid as a treatment for Clostridium difficile infection. According to Optimer President and Chief Executive Officer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics